• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Infertility - Pipeline Review, Q4 2010 - Product Image

Infertility - Pipeline Review, Q4 2010

  • Published: December 2010
  • 58 pages
  • Global Markets Direct

Infertility - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Infertility - Pipeline Review, Q4 2010”, provides an overview of the Women's Infertility therapeutic pipeline. This report provides information on the therapeutic development for Women's Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women's Infertility. “Women's Infertility-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Women's Infertility.
- A review of the Women's Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Infertility Overview
Therapeutics Development
An Overview of Pipeline Products for Infertility
Infertility Therapeutics under Development by Companies
Infertility Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Infertility Therapeutics Development
Vyteris, Inc.
Watson Pharmaceuticals, Inc.
Merck & Co., Inc.
ASKA Pharmaceutical Co., Ltd
Dong-A Pharmaceutical Co., Ltd.
Gedeon Richter Plc.
Ferring Pharmaceuticals
Merck KGaA
Protalix BioTherapeutics, Inc.
BioGeneriX AG
Glycotope GmbH
Universities/Institutes Involved in Infertility Therapeutics Development
Infertility Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
DA-3803 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Elonva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XM17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clomiphene citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clomiphene citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganirelix + suprefact - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hMG-IBSA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Letrozole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leuprolide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Microdose GnRh agonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Progesterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Infertility - Featured News
Jul 02, 2010: Watson Completes Acquisition Of CRINONE Product Line And Shares Of Columbia Laboratories
Mar 04, 2010: Columbia Laboratories Enters Into Purchase and Collaboration Agreement with Watsom Pharmaceuticals for Progesterone Franchise- Watson to acquire rights to CRINONE and PROCHIEVE
Feb 15, 2010: Merck Receives European Approval For Corifollitropin Alfa Injection Under The Brand Name ELONVA
Jul 01, 2009: Schering-Plough Presents Phase II and III Data For Corifollitropin Alfa
Jun 22, 2009: Cordex Signs European Development Partnership For Sperm Motility Drug ATPotent
Mar 10, 2009: Vyteris Initiates Phase II Clinical Trial of Infertility Treatment Using Smart Patch Technology
Jan 04, 2009: European Submission Of Fertility Medicine Corifollitropin Alfa Announced By Schering-Plough
Jul 09, 2008: Schering-Plough Fertility Drug SCH 900962 Aces Phase III
May 14, 2008: University Of Pennsylvania Study Demonstrates ATP Improves Sperm Motility And In Vitro Fertilization In Animals
Apr 01, 2008: VIVUS Completes Special Protocol Assessment For Phase 3 Efficacy Studies And Reaches Agreement With The FDA On The Safety Study For Luramist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos